Telix Pharmaceuticals (STU:T3X) Research & Development : €118.7 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Telix Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Telix Pharmaceuticals's Research & Development for the six months ended in Dec. 2024 was €66.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €118.7 Mil.

Telix Pharmaceuticals Research & Development Historical Data

The historical data trend for Telix Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Research & Development Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Research & Development

Get a 7-Day Free Trial

14.29

21.61

51.40

78.90

117.72

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Research & Development	Get a 7-Day Free Trial										35.57	18.86	60.21	51.93	66.80

Telix Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €118.7 Mil.

Telix Pharmaceuticals (STU:T3X) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Telix Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (STU:T3X) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

TLX:USA TLPPF:USA TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals Headlines

No Headlines